Siegfried’s shares surged 6.7% to CHF 83.4 on Friday after the Swiss contract development and manufacturing organization reported stronger-than-expected first-half 2026 results.
The company posted total revenue of CHF 633 million for the period, topping the CHF 621 million consensus among analysts. Organic growth reached 4.8% at constant exchange rates, exceeding the market’s forecast of 2.4%. Revenue in the Drug Substance division climbed to CHF 431 million, surpassing the CHF 408 million estimate, while Drug Product division sales totaled CHF 202 million, falling short of the CHF 212 million consensus.
Management reaffirmed its full-year guidance, providing reassurance after investor concerns earlier this year about concentration risk tied to a single large customer in the Drug Substance segment. The stock’s 52-week high stands at CHF 101.6, while the average 12-month price target among analysts remains at CHF 98.17 with a Buy rating.
The gains came as U.S. equities edged higher, with the S&P 500 up 0.3% and the Nasdaq advancing 0.5%.
